Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.

ESMO open·2026
Same author

A case of bullous fixed drug eruption induced by tenofovir disoproxil fumarate/ emtricitabine.

Annales de dermatologie et de venereologie·2026
Same author

Use of social media and alternative and complementary medicine in a cohort of 1053 patients with hidradenitis suppurativa.

Annales de dermatologie et de venereologie·2026
Same author

Risk of persistent hypogammaglobulinaemia in children with autoimmune bullous dermatoses treated with rituximab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Autoimmune bullous dermatosis in children: French guidelines.

Annales de dermatologie et de venereologie·2025
Same author

Prevalence of tattoos in a cohort of 1053 patients with hidradenitis suppurativa.

Annales de dermatologie et de venereologie·2025

Related Experiment Videos

[Telangiectasia during amlodipine therapy].

A-S Dussouil1, C Gaudy-Marqueste, A-M Tasei

  • 1UMR 911, Inserm centre de recherche en oncologie biologique et oncophamacologie CRO2, service de dermatologie, hôpital de la Timone, Aix-Marseille université, Assistance Publique des Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France. annesophie.dussouil@gmail.com

Annales De Dermatologie Et De Venereologie
|March 8, 2013
PubMed
Summary

Amlodipine, a calcium channel blocker for hypertension, may cause telangiectasias. Discontinuing amlodipine led to the regression of these vascular lesions in a patient, suggesting a causal link.

Related Experiment Videos

Area of Science:

  • Dermatology
  • Cardiology
  • Pharmacology

Background:

  • Calcium channel blockers are first-line hypertension treatments.
  • Amlodipine is a common dihydropyridine calcium channel blocker.
  • Telangiectasias are dilated superficial blood vessels.

Observation:

  • A 63-year-old woman developed asymptomatic stellate telangiectasias on her trunk and upper limbs.
  • The patient was on amlodipine for 5 years for essential hypertension.
  • Histology revealed dilated superficial dermal capillaries without inflammation.

Findings:

  • Amlodipine discontinuation resulted in spontaneous regression of telangiectasias.
  • The patient experienced no relapse after one year of follow-up.
  • This case suggests a potential link between amlodipine and telangiectasia formation.

Implications:

  • Calcium channel blockers, particularly amlodipine, may induce telangiectasias.
  • Vasodilatation from calcium channel blockade could contribute to telangiectasia development.
  • Further research is needed to understand the mechanism and prevalence of this adverse effect.